cfDNA Methylation for Liver Cancer Recurrence Detection
Recruiting now
Conditions studied: Primary Liver Cancer
In brief
Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.
Key facts
- Study ID
- NCT07466602
- Run by
- Wuhan Ammunition Life-tech Co., Ltd
- People needed
- 500
- Starts
- 2025-09-02
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-03-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Primary liver cancer
You may not qualify if…
- Concurrent other malignant tumors;
- Ineligible for hepatectomy, liver transplantation, ablation, or TACE therapy;
- Negative methylation status prior to treatment.
Where it is running
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.